Synlogic announces decision to discontinue synpheny-3 study and provides corporate update

Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint data review found treatment to be safe and well-tolerated board of directors plans to perform assessment of strategic options cambridge, mass., feb. 08, 2024 (globe newswire) -- synlogic, inc. (nasdaq: sybx), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced today the decision to discontinue synpheny-3, its ongoing pivotal study of labafenogene marselecobac (synb1934) as a potential treatment for phenylketonuria (pku).
SYBX Ratings Summary
SYBX Quant Ranking